Edit the RNA. Keep the DNA. Fix the Disease.
AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.
Category Highly Important
Your Knee Called. It Wants New Cartilage.
Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.
No Drugs. Just Ultrasound.
SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.
The Denali Diaspora Hits the Clinic
Tenvie Therapeutics doses first patient in Phase 1 trial of CNS-penetrant NLRP3 inhibitor TNV262.
A Hundred Million Reasons to Pay Attention
Stipple Bio emerges from stealth with an oversubscribed $100M Series A to advance its precision oncology ADC platform.
One Bought a Podcast. The Other Bought a Lab.
Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.
Canada Bets $280M on Aspect Biosystems’ Bioprinted Tissue Therapeutics
Aspect Biosystems just landed $280M from the Canadian government to advance bioprinted cellular medicines — on top of a $115M Series B and a $2.7B Novo Nordisk deal.
Neutrolis Posts Positive Phase 1a Data for First-in-Class NET-Targeting Therapy
NTR-1011 is the first drug designed to dismantle neutrophil extracellular traps — and early safety data just cleared the way for lupus and RA patients.
A University Built a CAR-T Therapy From Scratch — And the FDA Said Yes
The University of Colorado Anschutz Gates Institute just became the first U.S. academic institution to take a fully in-house CAR-T from bench to IND — no pharma partner needed.
AvenCell Doses First Patient With Switchable Dual-Target CAR-T
AvenCell's AVC-203 is the first CRISPR-engineered allogeneic CAR-T with a switchable receptor to hit the clinic — and the timing couldn't be better.